CO2022017618A2 - Antagonistas del receptor de adenosina a2a - Google Patents

Antagonistas del receptor de adenosina a2a

Info

Publication number
CO2022017618A2
CO2022017618A2 CONC2022/0017618A CO2022017618A CO2022017618A2 CO 2022017618 A2 CO2022017618 A2 CO 2022017618A2 CO 2022017618 A CO2022017618 A CO 2022017618A CO 2022017618 A2 CO2022017618 A2 CO 2022017618A2
Authority
CO
Colombia
Prior art keywords
receptor antagonists
adenosine receptor
compounds
relates
present
Prior art date
Application number
CONC2022/0017618A
Other languages
English (en)
Inventor
Clive Mccarthy
Benjamin Moulton
Original Assignee
Adorx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006823.5A external-priority patent/GB202006823D0/en
Priority claimed from GBGB2019922.0A external-priority patent/GB202019922D0/en
Application filed by Adorx Therapeutics Ltd filed Critical Adorx Therapeutics Ltd
Publication of CO2022017618A2 publication Critical patent/CO2022017618A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula I mostrados a continuación: (I) en donde R0, R1, R2, R3 y A son cada uno como se define en la solicitud. La presente invención también se refiere a los procesos para la preparación de estos compuestos, a las composiciones farmacéuticas que los comprenden, y a su uso en el tratamiento de enfermedades o afecciones en las que está implicada la actividad del receptor de adenosina A2a, tales como, por ejemplo, el cáncer.
CONC2022/0017618A 2020-05-07 2022-12-06 Antagonistas del receptor de adenosina a2a CO2022017618A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006823.5A GB202006823D0 (en) 2020-05-07 2020-05-07 Antagonist compounds
GBGB2019922.0A GB202019922D0 (en) 2020-12-16 2020-12-16 Antagonist compounds
PCT/GB2021/051106 WO2021224636A1 (en) 2020-05-07 2021-05-06 Antagonists of the adenosine a2a receptor

Publications (1)

Publication Number Publication Date
CO2022017618A2 true CO2022017618A2 (es) 2023-02-16

Family

ID=75977772

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0017618A CO2022017618A2 (es) 2020-05-07 2022-12-06 Antagonistas del receptor de adenosina a2a

Country Status (16)

Country Link
US (1) US20230203041A1 (es)
EP (1) EP4146654A1 (es)
JP (1) JP2023525762A (es)
KR (1) KR20230035236A (es)
CN (1) CN115996929A (es)
AU (1) AU2021266433A1 (es)
BR (1) BR112022022437A2 (es)
CA (1) CA3181354A1 (es)
CL (1) CL2022003055A1 (es)
CO (1) CO2022017618A2 (es)
EC (1) ECSP22091613A (es)
GB (1) GB2609879B (es)
IL (1) IL297963A (es)
MX (1) MX2022013946A (es)
PE (1) PE20230769A1 (es)
WO (1) WO2021224636A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023138343A1 (zh) * 2022-01-18 2023-07-27 江苏亚尧生物科技有限公司 新型吡唑并嘧啶化合物及其组合物、制备方法和用途
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
EP2402337A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402345A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
US20190225689A1 (en) 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies

Also Published As

Publication number Publication date
US20230203041A1 (en) 2023-06-29
WO2021224636A1 (en) 2021-11-11
CN115996929A (zh) 2023-04-21
GB2609879B (en) 2023-08-16
GB2609879A (en) 2023-02-15
JP2023525762A (ja) 2023-06-19
MX2022013946A (es) 2023-02-01
PE20230769A1 (es) 2023-05-09
IL297963A (en) 2023-01-01
KR20230035236A (ko) 2023-03-13
AU2021266433A1 (en) 2022-12-15
ECSP22091613A (es) 2023-03-31
BR112022022437A2 (pt) 2023-01-03
CL2022003055A1 (es) 2023-07-07
EP4146654A1 (en) 2023-03-15
GB202217519D0 (en) 2023-01-04
CA3181354A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
CO2022017618A2 (es) Antagonistas del receptor de adenosina a2a
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
CL2018001484A1 (es) Dinucleotidas de purino ciclico como moduladores de estimulador de genes de interferon (sting).
CL2022003185A1 (es) Midazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b ((sol. div. 202002198)
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2019008684A2 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cancer
CU20110212A7 (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
ECSP21036982A (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
ECSP22022322A (es) Triazolopirimidinas como inhibidores de a2a/a2b
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
CO2022014876A2 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
MX2023001324A (es) Compuestos antagonistas.
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
CO2018003756A2 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida
MX2023006881A (es) Antagonistas del receptor de adenosina a2a.
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CL2023002635A1 (es) Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1